Active immunization therapies for Parkinson's disease and multiple system atrophy (Q38564102)

4 September 2017

1 reference

title

Active immunization therapies for Parkinson's disease and multiple system atrophy (English)

1 reference

4 September 2017

0 references

1 reference

1 reference

Achim Schneeberger

1

1 reference

4 September 2017

Lanay Tierney

series ordinal

2

1 reference

4 September 2017

Markus Mandler

series ordinal

3

1 reference

4 September 2017

language of work or name

English

0 references

publication date

11 August 2015

1 reference

4 September 2017

1 reference

4 September 2017

31

1 reference

4 September 2017

2

1 reference

4 September 2017

214-224

1 reference

Synucleinopathies: clinical and pathological implications

4 September 2017

1 reference

Alpha-synuclein in Lewy bodies

21 January 2018

1 reference

Lipid rafts mediate the synaptic localization of alpha-synuclein.

21 January 2018

1 reference

Role of Protein Aggregation in Mitochondrial Dysfunction and Neurodegeneration in Alzheimer's and Parkinson's Diseases

21 January 2018

1 reference

Immunotherapy targeting α-synuclein, with relevance for future treatment of Parkinson's disease and other Lewy body disorders

21 January 2018

1 reference

The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations

21 January 2018

1 reference

Genetic variants of the alpha-synuclein gene SNCA are associated with multiple system atrophy

21 January 2018

1 reference

Neurological and neurodegenerative alterations in a transgenic mouse model expressing human alpha-synuclein under oligodendrocyte promoter: implications for multiple system atrophy.

21 January 2018

1 reference

Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?

21 January 2018

1 reference

Staging of brain pathology related to sporadic Parkinson's disease

21 January 2018

1 reference

Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice

21 January 2018

1 reference

Transmission of multiple system atrophy prions to transgenic mice

21 January 2018

1 reference

Lewy body extracts from Parkinson disease brains trigger α-synuclein pathology and neurodegeneration in mice and monkeys.

21 January 2018

1 reference

Exosomal cell-to-cell transmission of alpha synuclein oligomers.

21 January 2018

1 reference

Dopamine promotes formation and secretion of non-fibrillar alpha-synuclein oligomers.

21 January 2018

1 reference

Alpha-synuclein cell-to-cell transfer and seeding in grafted dopaminergic neurons in vivo

21 January 2018

1 reference

Cell-to-cell transmission of α-synuclein aggregates

21 January 2018

1 reference

Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies

21 January 2018

1 reference

Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial.

21 January 2018

1 reference

Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice

21 January 2018

1 reference

AFFITOME® technology in neurodegenerative diseases: the doubling advantage

21 January 2018

1 reference

Site-specific UBITh amyloid-beta vaccine for immunotherapy of Alzheimer's disease

21 January 2018

1 reference

The second-generation active Aβ immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects.

21 January 2018

1 reference

Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease

21 January 2018

1 reference

Immunotherapy for Alzheimer's disease: rational basis in ongoing clinical trials.

21 January 2018

1 reference

Immunogenicity of epitope vaccines targeting different B cell antigenic determinants of human α-synuclein: feasibility study.

21 January 2018

1 reference

Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study

21 January 2018

1 reference

Experimental and clinical application of plasmid DNA in the field of central nervous diseases

21 January 2018

1 reference

Compacted DNA nanoparticle gene transfer of GDNF to the rat striatum enhances the survival of grafted fetal dopamine neurons

21 January 2018

1 reference

Prevention of onset of Parkinson's disease by in vivo gene transfer of human hepatocyte growth factor in rodent model: a model of gene therapy for Parkinson's disease

21 January 2018

1 reference

Immune effects of optimized DNA vaccine and protective effects in a MPTP model of Parkinson's disease.

21 January 2018

1 reference

Dendritic cell-based vaccine efficacy: aiming for hot spots

21 January 2018

1 reference

Therapeutic cancer vaccines: past, present, and future

21 January 2018

1 reference

Evaluation of an α synuclein sensitized dendritic cell based vaccine in a transgenic mouse model of Parkinson disease

21 January 2018

1 reference

Regulatory T cells in cancer immunotherapy

21 January 2018

1 reference

Nitrated alpha-synuclein immunity accelerates degeneration of nigral dopaminergic neurons

21 January 2018

1 reference

Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson's disease

21 January 2018

1 reference

Neuroimmunological processes in Parkinson's disease and their relation to α-synuclein: microglia as the referee between neuronal processes and peripheral immunity

21 January 2018

1 reference

Molecular chaperones in protein folding and proteostasis

21 January 2018

1 reference

Roles of heat-shock proteins in innate and adaptive immunity

21 January 2018

1 reference

The role of heat shock proteins in antigen cross presentation

21 January 2018

1 reference

Active immunization of mice with an Abeta-Hsp70 vaccine.

21 January 2018

1 reference

Amyloid beta-HSP60 peptide conjugate vaccine treats a mouse model of Alzheimer's disease.

21 January 2018

1 reference

Heat shock protein 70 inhibits alpha-synuclein fibril formation via preferential binding to prefibrillar species

21 January 2018

1 reference

Chaperone proteostasis in Parkinson's disease: stabilization of the Hsp70/alpha-synuclein complex by Hip

21 January 2018

1 reference

Chaperoned amyloid proteins for immune manipulation: α-Synuclein/Hsp70 shifts immunity toward a modulatory phenotype

21 January 2018

1 reference

Priorities in Parkinson's disease research

21 January 2018

1 reference

Phenylbutyrate up-regulates the DJ-1 protein and protects neurons in cell culture and in animal models of Parkinson disease

21 January 2018

1 reference

The c-Abl inhibitor, nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson's disease

21 January 2018

1 reference

Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin's ubiquitination and protective function

21 January 2018

1 reference

EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity.

21 January 2018

1 reference

Vaccination for Parkinson's disease

21 January 2018

1 reference

Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials

21 January 2018

1 reference

Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy

21 January 2018

1 reference

Exploratory activity and motor coordination in old versus middle-aged C57BL/6J mice.

21 January 2018

1 reference

Behavioral characterization in a comprehensive mouse test battery reveals motor and sensory impairments in growth-associated protein-43 null mutant mice

21 January 2018

1 reference

beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease

21 January 2018

1 reference

Fluoxetine ameliorates behavioral and neuropathological deficits in a transgenic model mouse of α-synucleinopathy

21 January 2018

1 reference

Alzheimer's disease drug-development pipeline: few candidates, frequent failures

21 January 2018

1 reference

The usefulness and challenges of transgenic mouse models in the study of Alzheimer's disease

21 January 2018

1 reference

Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature.

21 January 2018

1 reference

Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression

21 January 2018

1 reference

High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease

21 January 2018

1 reference

The natural history of treated Parkinson's disease in an incident, community based cohort

21 January 2018

1 reference

Multiple system atrophy: natural history, MRI morphology, and dopamine receptor imaging with 123IBZM-SPECT

21 January 2018

1 reference

Neuropathology of non-motor features of Parkinson disease

21 January 2018

1 reference

Cerebellar role in fear-conditioning consolidation

21 January 2018

1 reference

Grading of neuropathology in multiple system atrophy: proposal for a novel scale

21 January 2018

1 reference

Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein.

21 January 2018

1 reference

Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy.

21 January 2018

1 reference

Mutation in the alpha-synuclein gene identified in families with Parkinson's disease

21 January 2018

1 reference

Caught in the act: alpha-synuclein is the culprit in Parkinson's disease

21 January 2018

1 reference

Genomic investigation of alpha-synuclein multiplication and parkinsonism

21 January 2018

1 reference

alpha-Synuclein locus triplication causes Parkinson's disease

21 January 2018

1 reference

Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease

21 January 2018

1 reference

Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease

21 January 2018

1 reference

Genome-wide association study reveals genetic risk underlying Parkinson's disease

21 January 2018

1 reference

SNCA variants are associated with increased risk for multiple system atrophy

21 January 2018

1 reference

Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein.

21 January 2018

1 reference

Olfactory deficits in mice overexpressing human wildtype alpha-synuclein

21 January 2018

1 reference

Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein

21 January 2018

1 reference

Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders

21 January 2018

1 reference

Transgenic animal models of neurodegenerative diseases and their application to treatment development

21 January 2018

1 reference

Hippocampal tau pathology is related to neuroanatomical connections: an ageing population-based study.

21 January 2018

1 reference

Diagnosis and treatment of Parkinson disease: molecules to medicine

21 January 2018

1 reference

Molecular events underlying Parkinson's disease - an interwoven tapestry

21 January 2018

1 reference

Nitrated {alpha}-synuclein-induced alterations in microglial immunity are regulated by CD4+ T cell subsets

21 January 2018

1 reference

α-Synuclein vaccination prevents the accumulation of parkinson disease-like pathologic inclusions in striatum in association with regulatory T cell recruitment in a rat model

21 January 2018

1 reference

Genetics of Parkinson's disease and biochemical studies of implicated gene products: Commentary

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/MDS.26377

1 reference

4 September 2017

1 reference